Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma - Wikidata - awgldk - TriplyDB

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma

http://www.wikidata.org/entity/Q33618658

about

Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.Melatonin enhances sorafenib actions in human hepatocarcinoma cells by inhibiting mTORC1/p70S6K/HIF-1α and hypoxia-mediated mitophagy.Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial.A novel chemotherapeutic sensitivity-testing system based on collagen gel droplet embedded 3D-culture methods for hepatocellular carcinoma.PKN2 in colon cancer cells inhibits M2 phenotype polarization of tumor-associated macrophages via regulating DUSP6-Erk1/2 pathway.Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma

P2860

Q47110143-C30F34A7-6618-434C-B418-B86BE1D489BC Q47115627-FEC2513C-EF81-4FAC-AF38-C9144FB73FF7 Q47144193-A27D802D-8893-4ABA-AFFB-B6370A95EE21 Q47158994-13A2CD8B-244F-4904-AE3B-652CA7565D44 Q48524121-8917DC5B-5E69-47C5-B7DF-7A9F4BBF39C1 Q58701446-B6F85A92-B5B0-4F13-9926-07580BAB60E7

P2860

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma

http://www.wikidata.org/entity/Q33618658

description

2017 nî lūn-bûn

@nan

2017 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma

@ast

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma

@en

type

label

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma

@ast

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma

@en

prefLabel

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma

@ast

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma

@en

P1433

Q33618658-13DFEF2D-81C8-487A-8348-9A06B0ED6BE8

P1476

Q33618658-95E37DF0-687F-4D46-9A66-9B55A16C8E8D

P2093

Q33618658-03DE31B4-460D-4D99-89F2-3D51C1F29FC2

Q33618658-076C1A83-ACC3-414C-81D0-74556524B396

Q33618658-17F53901-9769-421B-B179-215349B88D4D

Q33618658-1C0093EC-6E01-4D23-AB1D-CF58EF79DFEA

Q33618658-37EF1F4D-A77B-4742-8E58-DEE41FE56D71

Q33618658-5491CF6B-57A8-483C-899E-EB23A22E573E

Q33618658-AAC38AB3-0FC6-4778-AB4E-08E141034CE5

Q33618658-C718C55C-4E70-42D4-BD63-26537A248EE8

Q33618658-DAD4351D-C4BF-4B6D-B173-0AE5756A5EB9

Q33618658-EF32A1BD-10A8-4594-A889-D11B78BFEB22

P2860

Q33618658-1416B60B-C671-45F0-9EFE-8195B9D0CA85

Q33618658-1BA9B829-BDE8-42B6-9878-C42AB11395F8

Q33618658-2188D2AC-9468-4873-9DFA-79957C52A783

Q33618658-265DFDC9-CE67-4D7E-9388-54F6849E42E5

Q33618658-266EA17B-142D-47BE-A3B1-067D8C8274D2

Q33618658-37838702-9F51-4426-85EB-1164035805B5

Q33618658-4CF8E775-DD87-4C81-9E81-A6298E9691D0

Q33618658-5DED8D36-3AE0-4ABE-B26E-10BC578D1CCA

Q33618658-5FFFF04A-781F-4127-934B-3A1F4D4ED038

Q33618658-67842FC6-3941-4F52-9FCB-E1FBD515390C

P304

Q33618658-5822A5B1-FA9F-457B-AF51-7A3DAFECF70C

P31

Q33618658-58CA09D6-DDBC-4322-BB48-98B78839C04E

P356

Q33618658-B97B046E-4846-4B45-8A42-532007346200

P407

Q33618658-2FB58F68-A84B-4847-A7B7-41BB2112BC20

P433

Q33618658-DAB5D2E6-3B07-4D78-94E0-5B92B3049F28

P478

Q33618658-0E1F059D-97B8-4E69-A6CE-3C2674BBC627

P577

Q33618658-3C9D5F24-223B-4AF7-903C-2672FEB3D052

P698

Q33618658-F3039FCF-93FB-40F7-8EC3-34976B9BAFF4

P932

Q33618658-98BE9603-A50D-404F-9117-4DE7DC3E11B1

P356

ONCOTARGET.15575

P1433

P1476

Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma

@en

P2093

AiMin Li

http://www.w3.org/2001/XMLSchema#string

Biao Wang

http://www.w3.org/2001/XMLSchema#string

DingLi Liu

http://www.w3.org/2001/XMLSchema#string

Hang Zheng

http://www.w3.org/2001/XMLSchema#string

JinZhang Chen

http://www.w3.org/2001/XMLSchema#string

RongCheng Luo

http://www.w3.org/2001/XMLSchema#string

WanFu Xu

http://www.w3.org/2001/XMLSchema#string

YaHui Liu

http://www.w3.org/2001/XMLSchema#string

Yang Cheng

http://www.w3.org/2001/XMLSchema#string

Yun Zhu

http://www.w3.org/2001/XMLSchema#string

P2860

Risk factors of hepatocellular carcinoma--current status and perspectives

Sorafenib in advanced hepatocellular carcinoma

Membrane-to-Nucleus Signals and Epigenetic Mechanisms for Myofibroblastic Activation and Desmoplastic Stroma: Potential Therapeutic Targets for Liver Metastasis?

HGF and direct mesenchymal stem cells contact synergize to inhibit hepatic stellate cells activation through TLR4/NF-kB pathway

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

TLR4 enhances TGF-beta signaling and hepatic fibrosis

Fluvastatin mediated breast cancer cell death: a proteomic approach to identify differentially regulated proteins in MDA-MB-231 cells.

Toll-like receptor 4 signaling promotes epithelial-mesenchymal transition in human hepatocellular carcinoma induced by lipopolysaccharide.

Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.

Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells.

P304

23265-23276

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.15575

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28423574

http://www.w3.org/2001/XMLSchema#string

P932

5410302

http://www.w3.org/2001/XMLSchema#string